Documentary operationalisation of research training in European Clinical Pharmacology: a graded pattern across current national training documents

Introduction In several European health systems, specialist training in Clinical Pharmacology prepares physicians to lead early-phase trials and Clinical Trials Units, pharmacovigilance activities and interactions with medicines regulators. Whether national training documents operationalise that research training—as verifiable, assessable activities rather than declared competencies alone—has not been measured from the authoritative national sources. Methods We performed a cross-sectional documentary analysis of the current national regulations or official curricula governing the 20 formally recognised Clinical Pharmacology specialist qualifications (primary or additional) in the EU/EEA, the United Kingdom and Switzerland for which a national training document was publicly accessible. Seven research-relevant dimensions were scored 0, 0.5 or 1 by two investigators, each blinded to the other’s ratings (Cohen’s κ = 0.84 unweighted, 0.87 quadratic-weighted; 90.7% agreement). Two near-universal dimensions (Phase I–IV trial design and pharmacovigilance) are reported separately; the five operationalisation dimensions—a mandatory assessed research output, mandated Good Clinical Practice training, assessed biostatistics/pharmacoepidemiology, Phase I/Clinical Trials Unit exposure and documented medicines-authority interaction—were combined into an operationalisation index (0–100). Results Pharmacovigilance was codified in all 20 programmes, while Phase I–IV trial design was explicit in 18 and partially specified in two. The index formed a graded distribution from 30 to 90 (Sarle’s bimodality coefficient 0.41; every 10-point level occupied; no programme at the ceiling), and no sensitivity specification yielded a separated distribution. Descriptively, the index showed little relationship with programme length (24–72 months) or entry route; median values were 60 in examination-based programmes and 40 in systems using programmatic assessment without a discrete final specialist examination. The UEMS repository holds texts that predate the current regulation for nine of the 17 countries with an entry and omits three currently regulated qualifications. Discussion Country positions reflect what a document codifies—not training delivery, research capacity or activities required elsewhere—as the Sweden (lowest)–Croatia (highest) contrast illustrates. The scores did not form two clearly separated groups but a graded continuum of documentary operationalisation, which provides a descriptive baseline for discussing verifiable minimum requirements in a future European Training Requirements document.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-19
DOI
https://doi.org/10.3389/fphar.2026.1992498
Primary Topic
Health and Medical Research Impacts
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Documentary operationalisation of research training in European Clinical Pharmacology: a graded pattern across current national training documents

Beatriz Alonso, Blanca Sánchez-Santiago, Galo Peralta
Frontiers in Pharmacology
Health and Medical Research Impacts
article

Documentary operationalisation of research training in European Clinical Pharmacology: a graded pattern across current national training documents

Beatriz Alonso, Blanca Sánchez-Santiago, Galo Peralta
article en

Abstract

Introduction In several European health systems, specialist training in Clinical Pharmacology prepares physicians to lead early-phase trials and Clinical Trials Units, pharmacovigilance activities and interactions with medicines regulators. Whether national training documents operationalise that research training—as verifiable, assessable activities rather than declared competencies alone—has not been measured from the authoritative national sources. Methods We performed a cross-sectional documentary analysis of the current national regulations or official curricula governing the 20 formally recognised Clinical Pharmacology specialist qualifications (primary or additional) in the EU/EEA, the United Kingdom and Switzerland for which a national training document was publicly accessible. Seven research-relevant dimensions were scored 0, 0.5 or 1 by two investigators, each blinded to the other’s ratings (Cohen’s κ = 0.84 unweighted, 0.87 quadratic-weighted; 90.7% agreement). Two near-universal dimensions (Phase I–IV trial design and pharmacovigilance) are reported separately; the five operationalisation dimensions—a mandatory assessed research output, mandated Good Clinical Practice training, assessed biostatistics/pharmacoepidemiology, Phase I/Clinical Trials Unit exposure and documented medicines-authority interaction—were combined into an operationalisation index (0–100). Results Pharmacovigilance was codified in all 20 programmes, while Phase I–IV trial design was explicit in 18 and partially specified in two. The index formed a graded distribution from 30 to 90 (Sarle’s bimodality coefficient 0.41; every 10-point level occupied; no programme at the ceiling), and no sensitivity specification yielded a separated distribution. Descriptively, the index showed little relationship with programme length (24–72 months) or entry route; median values were 60 in examination-based programmes and 40 in systems using programmatic assessment without a discrete final specialist examination. The UEMS repository holds texts that predate the current regulation for nine of the 17 countries with an entry and omits three currently regulated qualifications. Discussion Country positions reflect what a document codifies—not training delivery, research capacity or activities required elsewhere—as the Sweden (lowest)–Croatia (highest) contrast illustrates. The scores did not form two clearly separated groups but a graded continuum of documentary operationalisation, which provides a descriptive baseline for discussing verifiable minimum requirements in a future European Training Requirements document.

Frontiers in PharmacologyVol. 17
Marqués de Valdecilla University Hospital (ES), Instituto de Investigación Marqués de Valdecilla (ES)
Health and Medical Research Impacts
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon